NBI 6024
Latest Information Update: 28 Feb 2011
At a glance
- Originator Neurocrine Biosciences
- Class Antihyperglycaemics; Insulins; Peptide fragments
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Type 1 diabetes mellitus
Most Recent Events
- 28 Oct 2005 Neurocrine Biosciences has completed enrolment in a phase II trial for Type-1 diabetes in USA
- 16 Jun 2004 Data presented at the 64th Annual Scientific Sessions of the American Diabetes Association (ADA-2004) have been added to the Diabetes pharmacodynamics section
- 06 May 2004 Neurocrine Biosciences has completed enrolment in a phase II trial in patients with new onset of Type-1 diabetes mellitus